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AbbreviAtioNS
Blimp1 B-lymphocyte induced maturation  
 protein 1 
CLP common lymphoid progenitor 
CMP common myeloid progenitor 
DC dendritic cell 
EBF early B cell factor 
ELP early lymphoid progenitor 
ETP early thymic progenitor 
EPLM early progenitor of lymphoid and  
 myeloid developmental potential 
Flt3 fms-like tyrosine kinase 3 
Flt3L fms-like tyrosine kinase 3 ligand
HSC hematopoietic stem cell 
MCSFR macrophage colony stimulating 
 factor receptor
MPP multi-potent progenitor
NK natural killer
XBP-1 X-box binding protein 1
ACKNowLedgeMeNtS
This research was supported by a Pfizer 
Australia Research Fellowship (to S.L.N.), 
an Erwin Schrödinger Fellowship/Austria (to 
S.C.) and the National Health and Medical 
Research Council of Australia.
AbStrACt
The transcription factor Pax5 is required for many aspects of B‑lymphopoiesis including 
lineage commitment, immunoglobulin rearrangement, pre‑BCR signalling and mature 
B cell survival. Pax5 regulates B cell lineage commitment by concurrently activating B cell 
specific gene expression as well as suppressing the expression of genes associated with 
non‑B cell fates. The identity of the molecular targets of Pax5‑mediated gene repression is 
the subject of much current interest. Recent studies have documented the essential nature 
of the Pax5 mediated repression of the stem cell transcriptional program, as well as the 
silencing of lineage inappropriate gene expression, for B cell development. Surprisingly 
the repression of genes by Pax5 continues throughout lymphopoiesis, with the loss of Pax5 
in mature B cell resulting in the reactivation of the same Pax5 targets during plasma cell 
differentiation. These recent insights into the mechanism of action of Pax5 in controlling 
B cell identity will be discussed.
tHe FuNCtioN oF Pax5 iN b CeLL CoMMitMeNt
All lineages of the blood, including B cells, are derived from a rare population in 
the bone marrow, the hematopoietic stem cell (HSC). HSC reside in specialized niches 
in the bone marrow and possess the unique capacities of self-renewal and the ability to 
differentiate into all the different mature blood cell types. One of the earliest differentiated 
progeny of the HSC is the multi-potent precursor (MPP), which is at the bifurcation of 
myeloid and lymphoid lineages.1 MPP can further differentiate into common myeloid 
progenitors (CMP) or early lymphoid progenitors (ELP) but have limited ability to 
self-renew. ELP themselves give rise to the early thymic T cell progenitor (ETP) or the 
common lymphoid progenitor (CLP).2 CLPs have B cell, natural killer (NK) cell, dendritic 
cell (DC), but limited T cell, potential. The first B cell progenitor arises from the CLP in 
the bone marrow and is variously termed the pre-pro B cell, fraction A, or CLP-2 and can 
be identified by the expression of the B cell specific marker B220.3
One of the earliest regulatory events associated with lymphoid development is the 
expression of the fms-like tyrosine kinase 3 (Flt3) on a subset of MPP and CLP.1,4 Flt3 
and Flt3L-deficient mice display a marked decrease in B cell progenitors and their HSCs 
are impaired in their ability to differentiate into myeloid and lymphoid cells.5-7 Flt3 
ligand (Flt3L) also plays an important role in the generation of DCs.8 The signalling 
pathway through which Flt3 selectively favours the generation of B cell progenitors over 
other lineages such as DC is currently unknown. The other essential growth factor for 
early lymphopoiesis is IL-7.9-11 The IL-7 receptor (IL-7R) is composed of the common 
g chain and the IL-7Ra chain, which is also a component of the thymic stromal derived 
lymphopoietin receptor (TSLP-R).12 In keeping with its dual role, IL-7Ra deficient mice 
have a more pronounced B cell deficiency than common g chain‑/‑ mice which have an 
intact TSLP-R.13,14 Interestingly, mice doubly deficient for Flt3L (or Flt3) and IL-7Ra 
lack any B cells demonstrating that together IL-7 and Flt3L are essential for virtually all B 
cell development.15,16
Specification and commitment of B lymphopoiesis also critically depends on the 
expression of a number of transcription factors: Ikaros, PU.1, E2A, Early B cell factor 
(EBF) and Pax5.17,18 While the exact functions of Ikaros and PU.1 in lymphoid 
progenitors is still unclear, Ikaros deficient mice lack Flt3 expression,19,20 whereas PU.1 
is known to promote the initiation of IL‑7Ra21 and EBF expression.22,23 Once defined B 
lymphoid progenitors are formed, the transcription factors E2A and EBF act in concert to 
initiate the expression of B cell specific genes in the earliest B cell progenitors.24 Despite 
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initiating the expression of some B cell specific genes, 
these two factors do not induce commitment to the B 
cell lineage, a process that depends on Pax5.
Pax5 is a multifunctional transcriptional regulator 
that is expressed throughout the B cell lineage, from 
the pro-B cell stage until its down-regulation in plasma 
cells.17,18 In the absence of Pax5, B cell development 
is arrested at the early pro-B cell (or pre-BI) stage of 
differentiation, characterised by the expression of many 
B cell specific transcripts and D‑JH rearrangements at 
the IgH locus.25 Intriguingly, while being unable to 
differentiate into mature B cells, Pax5‑/‑ pro-B cells 
can be cultivated indefinitely in vitro in the presence 
of IL-7 and stroma. Most surprisingly, these pro-B 
cells are not committed to the B cell lineage and are 
capable of differentiating into a broad spectrum of 
hematopoietic cell types.26,27 The restoration of Pax5 
expression in deficient cells suppresses this multi-lineage 
potential, whereas the conditional inactivation of Pax5 
in pro-B cells reverts lineage commitment and again 
generates multi-potent cells.28 A similar capacity was 
subsequently reported for E2A‑/‑ lymphoid progenitors, 
a finding in keeping with the fact that these cells 
lack Pax5 expression.29 Recently a number of studies 
have sought to address the mechanism by which 
Pax5 initially promotes and then maintains lineage 
commitment. These recent insights into Pax5 function 
will be discussed in detail below.
Pax5 rePreSSeS NoN-b CeLL SPeCiFiC geNeS to ALLow b 
CeLL CoMMitMeNt
Gene expression analysis of HSCs and various uncommitted 
hematopoietic progenitors has shown that multi-potent cells maintain 
the concurrent expression of genes associated with different lineages. 
This phenomenon is termed “lineage priming” and it is proposed 
that stem cells or uncommitted progenitors maintain a relatively 
open chromatin configuration which often results in low-level 
expression of genes reflective of multiple incompatible lineage 
fates.30,31 By this model, differentiation and ultimately lineage 
commitment is expected to result in the progressive repression of this 
lineage-promiscuous gene expression until a stable transcriptional 
profile is reached. As Pax5 has the capacity to both activate and repress 
genes, it was hypothesized that this transcription factor may promote 
B cell lineage commitment by repressing the expression of lineage 
inappropriate genes. Indeed multi-potent Pax5‑/‑ pro-B cells were 
shown to maintain promiscuous expression of myeloid, erythroid, T 
and NK cell genes, despite expressing multiple B cell specific genes.26 
A striking feature of this lineage-priming was the expression of cell 
surface receptors, such as c‑fms (macrophage colony stimulating factor 
receptor (M‑CSFR)) or Notch1, which allowed Pax5-deficient pro-B 
cells to respond to external signals and differentiate into macrophages 
and T cells, respectively (Fig. 1).26,32,33 Reintroduction of Pax5 
expression into these cells leads to the repression of these non-B cell 
committed genes thus abolishing multi-lineage potential, whereas 
the inactivation of Pax5 in committed pro-B cells results in the re-
expression of these genes.28 These data support a model whereby 
Pax5 controls B cell fate both by activating B cell specific target 
genes promoting B-lymphopoiesis and simultaneously repressing the 
non-B cell fate. Recent studies have now addressed three previously 
unresolved issues: firstly, what is the crucial target(s) of Pax5 
repression in lineage commitment; secondly, how many genes are 
repressed by Pax5 in early and late B cell differentiation; and finally, 
how mechanistically does Pax5 achieve these functions.
rePreSSioN oF FLt3 by Pax5 iS CruCiAL For b CeLL 
CoMMitMeNt
As Pax5 expression directly results in B cell commitment, we 
hypothesized that one strategy by which it promotes this process 
is to repress the expression of genes required to maintain stem cell 
fate. As mentioned above, expression of Flt3 on early hematopoietic 
progenitors is important for multi-lineage potency and the generation 
of B cell progenitors. Interestingly, B cells down-regulate Flt3 
expression during B cell commitment.34 Thus Flt3 represented an 
attractive candidate for Pax5 repression. Indeed, we have recently 
reported that, in contrast to the great majority of wild type pro-B 
cells (B220+ckit+), Pax5‑/‑ pro-B cells uniformly express Flt3 on 
their cell surface, suggesting that Pax5 may be involved in directly 
repressing Flt3 expression.35 In agreement with this prediction, the 
restoration of Pax5 in the mutant pro-B cells led to the rapid silencing 
of Flt3. Promoter analysis indicated that this repression is likely to 
be direct as we identified two Pax5 binding sites within the Flt3 
promoter region that are occupied in vivo. To test the importance 
of the Pax5-mediated repression of Flt3 in B cell commitment we 
used a retroviral vector to ectopically express Flt3 throughout the 
hematopoietic system and analyzed the consequences for B cell 
development.35 Strikingly, enforced Flt3 expression resulted in a 
pronounced decrease in all stages of bone marrow B-lymphopoiesis 
in transplanted mice while thymocyte and myeloid differentiation 
was relatively unaffected. This impaired B cell differentiation was 
also observed in vitro after the transduction of stem cell enriched 
populations and was not the result of Flt3-induced cell death.
Figure 1. Pax5‑mediated gene repression is essential for B cell lineage commitment. The 
key transcription factors and growth factor receptors are shown. Lymphoid progenitors are 
capable of “latent” myeloid differentiation in certain circumstances. ↓ Indicates positive 
interactions and ^ indicates repression. Genes dependent on Pax5 are indicated by a 
hatched line. In the absence of Pax5, pro‑B cells remain multipotent and can differentiate 
into myeloid and T cells.
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The importance of Pax5 mediated repression of Flt3 has recently 
received independent confirmation by the report that high doses of 
injected Flt3L results in a pronounced increase in the frequency of a 
population of the wild type progenitor cells termed the EPLM (early 
progenitor of lymphoid and myeloid developmental potential).36 
EPLMs appear to have phenotypic and developmental capacities very 
similar to Pax5‑/‑ pro B cells, demonstrating that the developmental 
pathway characterized in the absence of Pax5 also occurs in a transient 
manner in wild type cells.37 Importantly Flt3L exposure also resulted 
in a marked decrease in B lymphocyte progenitors, whereas myeloid 
and T cells were again unaffected.36 As in vitro studies have clearly 
shown that high levels of Flt3L can induce DC potential in a variety 
of progenitors,8,38 we propose that the inability of Pax5‑/‑ pro B 
cells to silence Flt3 expression enables these multi-potent cells to 
be influenced by other signals and thus allow the commitment to 
alternate lineages, such as DC, at the expense of B cells.
In summary, this data demonstrates how factors such as E2A and 
EBF that induce Pax5 expression and ultimately lineage commitment 
can at the same time result in the repression of Flt3, promoting B 
lineage commitment by a negative feedback mechanism (Fig. 1).
CoNtiNuouS Pax5 exPreSSioN iS eSSeNtiAL For tHe 
rePreSSioN oF LiNeAge iNAPProPriAte geNeS
One of the limitations to fully understanding the function(s) 
of Pax5 in B cells was the fact that, until recently, few of the genes 
repressed by Pax5 were known. To overcome this limitation, Delogu 
et al have utilised a global transcriptional profiling approach to 
identify and validate 110 Pax5 repressed genes in pro-B and mature B 
cells.39 Collectively these genes have important functions in a broad 
range of biological activities including cell-cell communication, 
adhesion, migration, nuclear processes and cellular metabolism. In 
strong support of the lineage-priming model, 68% of these repressed 
genes are also expressed in erythro-myeloid or T cell lineages and a 
substantial fraction of these are found in multi-potent progenitor 
fractions such as HSC, CMP and CLP.
The Pax5-mediated repression of these genes is not only critical 
for B cell commitment but is also important in maintaining B cell 
identity and function of committed pro-B cells, as inactivation of 
Pax5 in pro-B cells induced the rapid expression of a large number of 
previously repressed genes.39 This capability formally demonstrates 
that the ectopic expression of these genes in Pax5‑/‑ pro-B cells 
was not a result of incomplete lineage specification, but an active 
repression process dependent on Pax5. Furthermore, this repression 
was still essential in mature B cells as the deletion of Pax5 resulted 
in the re-expression of many of the formerly silent genes, including 
Flt3 (Fig. 2).
In contrast to early B cell development where Pax5 expression 
is maintained constitutively, Pax5 is normally down-regulated 
during the terminal differentiation of activated B cells into antibody 
secreting plasma cells.40 Delogu et al therefore addressed whether 
the Pax5-mediated repression of non-B cell specific genes is also 
alleviated after the physiological down-regulation of Pax5 during 
plasma cell differentiation. Indeed, many repressed genes were 
reexpressed in plasma cells due to the absence of Pax5 expression 
(Fig. 2). This re-expression was not an irrelevant consequence of the 
loss of Pax5 as two proteins, the coreceptor CD28 and the chemokine 
receptor CCR2, were shown to be important for plasma cell function 
in an immune response.39
Interestingly, the conditional deletion of Pax5 in mature B cells 
also resulted in the expression of Blimp‑1 (B lymphocyte induced 
maturation protein, also termed Prdm1), an essential transcriptional 
regulator of plasma cell development,41 and the J chain, a known 
Pax5-repressed gene required for efficient antibody secretion.42 Using 
chicken DT40 cells as an independent model, Nera et al also noted 
the activation of the plasmacytic transcription factors Blimp-1 and 
X-box binding protein 1 (XBP-1)43 and increased IgM secretion after 
Pax5 inactivation.44 Together these studies suggest that Pax5 normally 
functions in mature B cells to repress the plasma cell pathway through 
suppressing, directly or indirectly, Blimp‑1 expression. As Blimp-1 is 
known to directly repress Pax5 expression,45 it was proposed that the 
mutually antagonistic functions of these two pivotal transcription 
factors controls B cell terminal differentiation. However, recent 
experiments from our laboratory suggest that this interaction is 
more complex than anticipated, as the derepression of Pax5 target 
genes occurs in the absence of Blimp-1, suggesting that other factors 
are also essential in controlling Pax5 activity during B cell terminal 
differentiation (Fig. 2 and Kallies et al., submitted).
Pax5 CAN rePreSS geNe exPreSSioN by direCtLy 
iNterFeriNg witH tHe trANSCriPtioNAL MACHiNery
An important question that arises as a consequence of the 
observations outlined above is, how does Pax5 function on a 
molecular level to achieve the repression of this diverse range of genes? 
While in vitro biochemical studies have shown that Pax5 can directly 
repress gene transcription by recruiting members of the groucho 
family of corepressors, this interaction has not been demonstrated 
to be functionally relevant on endogenous Pax5 target genes.46 
Moreover, while Pax5 represses the expression of a large number of 
myeloid genes in B cells, the enforced over-expression of Pax5 in the 
myeloid lineage has no pronounced effect.32,47 A recent study using 
the c‑fms locus (encoding the MCSF-R) as a model Pax5-repressed 
gene has shed some light on this issue.48 Interestingly, the c‑fms locus 
is in an active or open chromatin configuration in Pax5‑/‑ pro-B 
cells whereas upon re-expression using an inducible system Pax5 
is rapidly recruited to the c‑fms promoter. This recruitment results 
in the immediate cessation of transcription as measured by the 
selective loss of RNA polymerase II localization. Pax5 induction 
Figure 2. The function of Pax5 and Blimp‑1 in late B cell differentiation. The 
stages of cellular differentiation from a resting B cell to an antibody secreting 
plasma cell are indicated, as are the relative levels of Pax5 and Blimp‑1 
expression. Pax5 represses non‑B cell and plasma cell genes in immature 
and naïve B cells. Upon activation, Pax5 function is inhibited and the 
expression of Pax5‑repressed genes such as Flt3 and ultimately Blimp‑1 are 
induced. A number of Pax5‑repressed genes are then important for plasma 
cell function.
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also leads to a delayed decrease in the binding of PU.1, an essential 
regulator of c‑fms expression in macrophages.48 DNA binding 
analysis indicated that Pax5 bound to the c‑fms promoter directly 
adjacent to a PU.1 site, and that Pax5 inhibited PU.1 function but 
not binding. The model to emerge from these studies proposes that 
in cells expressing high levels of c‑fms, such as macrophages, the full 
complement of transcription factors are present and drive maximal 
transcription. In this scenario, ectopic Pax5 has minimal impact and 
explains to lack of a functional consequence of Pax5 overexpression 
in myeloid cells. However, in lymphoid progenitors, the c‑fms locus 
is in an accessible or primed chromatin configuration but lacks the 
expression and/or concentration of essential myeloid factors such 
as PU.1.49 This configuration leads to low-level transcription that 
is repressed by Pax5 throughout B-lymphopoiesis. This concept 
provides a molecular rationale for lineage priming and indicates how 
the antagonistic interactions of a few master-regulatory transcription 
factors can control many important cell fate and differentiation 
decisions (Fig. 1). It remains to be determined whether the specifics 
of this model can be more broadly generalized as a mechanism to 
explain Pax5-mediated gene repression.
CoNCLuSioN
The control of B cell development by Pax5 represents one of the 
leading model systems to investigate the transcriptional regulation of 
hematopoietic cell differentiation choices. Interestingly, Pax5 controls 
many aspects of B cell biology including lineage commitment, antigen 
receptor rearrangement and signalling, and the control of terminal 
differentiation. Obtaining a cellular and molecular understanding 
of how one factor can achieve all these disparate functions has 
proven a difficult challenge. However the recent cataloguing of Pax5 
repressed genes as well as the development of plausible cellular and 
molecular models to understand Pax5-mediated gene repression are 
shedding light on these processes. These advances have highlighted 
the synergistic benefit of pursuing a variety of approaches, including 
global genomic, biochemical and precise gene-by-gene strategies, in 
understanding the complex interplay between gene regulation and 
cellular differentiation.
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